Marta Santos-Relvas

Porto, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape.

CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape.

Journal: Cell communication and signaling : CCS

Published: August 21, 2025

Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages.

Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across Bladder Cancer Stages.

Journal: International journal of molecular sciences

Published: April 11, 2025

Trimmed N-glycans define aggressive gastric cancer and predict clinical outcomes.

Trimmed N-glycans define aggressive gastric cancer and predict clinical outcomes.

Journal: Theranostics

Published: February 06, 2025

GlycoAvatars: bead-coated membrane models for studying the cancer-immune cells interactome.

GlycoAvatars: bead-coated membrane models for studying the cancer-immune cells interactome.

Journal: Communications biology

Published: January 27, 2025

Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy.

Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy.

Journal: ACS nano

Published: March 27, 2024

E-selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor-prognosis signature in colorectal cancer.

E-selectin affinity glycoproteomics reveals neuroendocrine proteins and the secretin receptor as a poor-prognosis signature in colorectal cancer.

Journal: Molecular oncology

Published: March 27, 2024

Stool Glycoproteomics Signatures of Pre-Cancerous Lesions and Colorectal Cancer.

Stool Glycoproteomics Signatures of Pre-Cancerous Lesions and Colorectal Cancer.

Journal: International journal of molecular sciences

Published: March 01, 2024

Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.

Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.

Journal: International journal of molecular sciences

Published: February 12, 2024

A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy.

A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: December 17, 2023

Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.

Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.

Journal: iScience

Published: November 27, 2023

Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.

Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.

Journal: Theranostics

Published: September 23, 2021

Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 15, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026